<b>Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate:</b> <b>A Randomized Trial</b>

<b>Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate:</b> <b>A Randomized Trial</b>

<p dir="ltr">The aim of the present study is to examine the effect of empagliflozin on hepatic glucose production (HGP) and total-body norepinephrine (NE) turnover in subjects with and without type 2 diabetes (T2DM). 36 subjects with T2DM and 36 individuals without T2DM were randomiz...

Full description

Saved in:
Bibliographic Details
Main Author: Siham Abdelgani (17756772) (author)
Other Authors: Ahmed Khattab (13450109) (author), John M Adams (21580796) (author), Fahd Al-Mulla (191364) (author), Mohamed Abu-Farha (25322) (author), Gozde Baskoy (9568356) (author), Jehad Abubaker (437067) (author), Aurora Merovci (21580797) (author), Ralph A DeFronzo (17756776) (author), Renata Belfort De Aguiar (21580798) (author), Muhammad Abdul-Ghani (4707436) (author)
Published: 2025
Subjects:
Other biological sciences not elsewhere classified
Hepatic Glucose Production
Norepinephrine Spill-Over
Type 2 Diabetes
SGLT2 inhibitor
Empagliflozin
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items